Brii Bio gets all hands on deck for Covid-19 an­ti­body hunt, lever­ag­ing Chi­nese part­ner­s' work with re­cov­ered pa­tients

A preprint pa­per de­scrib­ing 206 mon­o­clon­al an­ti­bod­ies against SARS-Cov-2 iso­lat­ed from eight Covid-19 pa­tients in Chi­na at­tract­ed a small ral­ly on Twit­ter a few days ago, when Broad in­ves­ti­ga­tor David Liu dubbed it “very good news.”

Now Brii Bio is un­veil­ing some more good news: It’s part­ner­ing with the re­searchers be­hind that pa­per from Ts­inghua and 3rd Peo­ple’s Hos­pi­tal of Shen­zhen to bring some of those an­ti­bod­ies to the clin­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER